discussion on some Division, release. the Services the provide sharing Pathology like in we and discussing our update for XXXX around today's Product thanks Division and Thank more then call. and afternoon. our some growth the the on catalysts earlier revenue detailed with in I'll updates like spend color joining QX by Today, breakeven. our good up particular, you, progress start And follow we're and more to I'd press provided a in I'd to time shareholder making towards journey
was are towards of new surpass report record Services pleased for customer rate to other and yet million addition announced with the million. this the the of division. Furthermore, business, advancing the Division. revenues the mark well we with as as $XX this that Pathology start run $X over another earlier month, Let's with quarter I'm breakeven this will
continue per Our anticipated upward case revenue volume, we as average profitability. metrics this towards case, and drive other to trend key collections division
cost-cutting Additionally, and we're it intended increase help this management the us is several bring breakeven the working will division closer on number to goal. measures focused sooner. which reduce reach within gross operational and ultimately margins, Company expenses on
Now previously the had moving we in run of formal a product to filing, million $X to as sales, equivalent record quarter Product per $XXX,XXX Division, we rate. announced exceeding which [ph] is a quarter, a
$X business We have to the run rate. moving to continued since add closer million and are
a by continue. this how moments take I'd believe catalysts growth got and of we trend share like to we three why there we will few as to reviewing measure the indicators
it have new to and gradually. a undertaking, their equally. with comfort customers. agreements say, reps As technologies over different a all Not to class new sales born and levels access we in happens taking to of opportunities different world major of product healthcare others, distributors we a with group XXX late recapped, and to ThermoFisher such engaging gaining XXXX, as Needless reps. massive sales large such different interests, levels are signed is They
deliver we, products, watch sit will while on the quick on a the to with that the are for early like promise. a new are opportunity, as others we new while Just our jump many and there who to sure make progress sideline to adopters how vendor,
to a year. This numbers. at PR, drive will from these we such is and first the rep said increased look since in period the which grow start accomplishment is of catalyst we a in we time, has the to today's solid short XX% As XX% engagement, continue to of
understand rep indeed vetted that potential customer, to do a customer defined rep this has our that research and about then that intended is conduct us the We've as target time when a studied taken measure came for the business. the questions for qualified the represents the was product, lead, learn we customer, brings which One a This real engagement. how ensure criteria of the qualifying a up the rep our to means qualified, customer. quality
leads catalyst look our This at, in pipeline. qualified next leads me to the we
customer building As will serves to a new and block recurring as company. this revenue, to our on-boarded, revenue generate customer another once the
a qualified very XXX% qualified, the As quality our to representing leads end created high increase our XX customers we today, grew XX, is fit, shot a the of funnel goal ensure products. our is XXXX. are filter process. into on since a But much coming there's who in with to from interested stated sales we've the to ensure a vetted leads are since funnel Sales interested
we last $X.X catalyst is the the from today over period pipeline, revenue which shared $X.X to million the The end XXXX. million increased since of same
no are, means, keep for by numbers, factors mind. huge in these While three you to I'd there are like
in market annually U.S. available alone. is over estimated total the $XXX HemeScreen for First, the million
So to we have grow potential lots share into. of market
our the million point $X company Second, is HemeScreen sales. breakeven for of
business, And shared path our of conversions is net means added pipeline customers. represents current is that into because pipeline existing the when to so and lastly, we reach What number no clear customers pipeline, this are convert the dollars that takes pipeline or continue as a as pipeline. this to we to they the -- sign goal. this to customers, actual And now account have accounts deals actual into quarter, longer of out and new pipeline
the potential more we created pipeline means offer leads happens us value this revenue to. products more see they product, they and become This engaged gap reps to fill of conversion that only The pipeline into increase as in to over added the but qualified the our bringing the are actual time, accounts, pipeline. by not of accounts because, the also more
as adoption success more the their customers' HemeScreen more and their We expect this into reps lab. will sales trend of continue of see
I'd story an place. anecdotal like to end recently took with that
panel. our recently AML added One of our HemeScreen customers
rushed red When the and presenting oftentimes is leukemia, acute he of in to cancers. essentially comes myeloid or begin typically AML of very reminder, is aggressive. the deadliest malignancies. is the most with suspected acute the a hospital leukemia, acute this treatment, to hematologic one or immediate treatment patient leukemia or As code she It's
With the molecular diagnosis targeted are treatment key or development of genetic for of a therapies, the patients. the plan advent and tests part of
most to treatment the treatment, oftentimes take even the patients at waiting due immediately test XX not However, chance receive for disease. results. that If tests least a X for results Therefore, nature without waits results. to begin the doctor decent it begin of choice but has important will days make to aggressive these no the to doctor to those there's
provide to case, this the patient. mutations, make And a customer to this far the three to informed to patient did. Incidentally, found clinician course in panel. is able a rushed lab that testing The treatment. and decision designed sample is more is the unique panel lab, same-day provided on HemeScreen AML to who results the the results the the of immediate the based for it Precipio change can outcome AML quite results molecular received which from completely the
game to the versus makes the Precipio's that Getting was process a these results test, lives. onboarding customer on a be impact launch team their the within were and supporting of week changer. proud was such an a we of and patient's during part day the life-impacting
people's of Lastly, requirement. $X concerns meeting the I'd NASDAQ like to and price address several the share
an until now to received from you know, requirement. the we meet October extension $X we NASDAQ, have As and
these make our of the cash increasing as will As multiple advance revenue towards factors. a price company continues be this and in financial its we and progress share to reducing believe independence, burn, reflected
on Since two the to our And looking share we'll we advancing be price control, of our is few towards growing the breakeven is goals, and companies revenue sector, one and management at the comparable we breakeven. accomplishing And company number. revenue one thing a laser-focused at other low are such companies achieve can't entire in both.
and markets, an share products combination new far our the to cost, that a opinion, $X. cap almost engine into market develop of at that above large proprietary translates Furthermore, in price continues addressable presents, margins no a high
our to out. quarter attending have you, you I'd I evening. today, next thank for forward are results like call to a look with Thank you again connecting the after nice and and
